NasoVAX

Phase 2Biologic

Altimmune

NasoVAX is one of 10 biologic programs targeting Coronavirus Infectious Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronavirus Infectious DiseaseActive, not recruiting

Coronavirus Infectious DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Coronavirus Infectious Disease

#DrugCompanyPhaseTrials

Plaquenil

Alnylam Pharmaceuticals

Norvir

Revia

Colcrys

Alnylam Pharmaceuticals

Inomax

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—7

Ketalar

AAultman Health Foundation

Avastin

NasoVAX

1 10

Hydroxychloroquine Sulfate

Novartis

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Coronavirus Infectious Disease1 trial

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

Terminated· Altimmune logo

Altimmune·Phase 2·NCT04442230·48 enrolled

Immunogenicity1 trial

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Completed· Altimmune logo

Altimmune·Phase 2·NCT03232567·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NasoVAX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NasoVAX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NasoVAX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Altimmune company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Altimmune

NasoVAX

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Coronavirus Infectious Disease1 trial

Immunogenicity1 trial

References

Drug Info

Quick Facts

Related News